Explore the words cloud of the transMed project. It provides you a very rough idea of what is the project "transMed" about.
The following table provides information about the project.
EBERHARD KARLS UNIVERSITAET TUEBINGEN
|Coordinator Country||Germany [DE]|
|Total cost||3˙327˙702 €|
|EC max contribution||3˙327˙702 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2017-12-01 to 2021-11-30|
Take a look of project's partnership.
|1||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||coordinator||498˙432.00|
|2||HASKOLI ISLANDS||IS (REYKJAVIK)||participant||538˙290.00|
|3||LUNDS UNIVERSITET||SE (LUND)||participant||527˙318.00|
|4||RISE RESEARCH INSTITUTES OF SWEDEN AB||SE (BORAS)||participant||527˙318.00|
|5||UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA||IT (MODENA)||participant||516˙122.00|
|6||INOCURE SRO||CZ (PRAHA)||participant||464˙844.00|
|7||PAMGENE INTERNATIONAL BV||NL (DEN HAAG)||participant||255˙374.00|
|8||OCULIS EHF||IS (REYKJAVIK)||participant||0.00|
|9||SP PROCESS DEVELOPMENT AB||SE (BORAS)||participant||0.00|
|10||2-BBB MEDICINES BV||NL (LEIDEN)||partner||0.00|
|11||BIOLOG LIFE SCIENCE INSTITUTE, FORSCHUNGSLABOR UND BIOCHEMICA- VERTRIEB GMBH||DE (BREMEN)||partner||0.00|
|12||European Vision Institute EEIG||BE (BRUXELLES)||partner||0.00|
|13||HANNOVER CLINICAL TRIAL CENTER GMBH||DE (HANNOVER)||partner||0.00|
|14||NLO European Patent and Trademark||NL (Amsterdam)||partner||0.00|
Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable, even with a wealth of basic and pre-clinical research data available. To address this problem, transMed proposes an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development of treatments for RD.
The transMed consortium joins four academic groups (EKUT, UNIMORE, ULUND, HI) with four non-academic and SME partners (SPPD, INCU, Oculis, PamGene), and five partner organisations (2BBB, BIOLOG, NLO, HCTC, EVI) with intersectoral collaborations already ongoing. Each transMed partner will contribute specific critical expertise to a curriculum covering all major aspects of translational research: From basic research into disease mechanisms and target definition, to drug design and development, in vitro test systems and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation.
transMed builds on and integrates three relevant translational projects, which are at the early pre-clinical, late pre-clinical, and early clinical stages, respectively, to provide the project’s Early Stage Researchers with the broadest possible overview. The training is completed by e-lectures, the inclusion of dedicated conferences for young researchers, a secondment and hands-on course programme from industry to academia and vice versa, permitting further insight and networking in the European biotech industry. Altogether, transMed will offer its students the opportunity to obtain a competitive PhD degree in several critical areas of biomedical research, providing for a strong employability in both the private and public sector.
|Communication and dissemination I||Documents, reports||2020-04-16 14:24:21|
|Dissemination material||Documents, reports||2020-04-16 14:24:16|
|Project website||Websites, patent fillings, videos etc.||2020-04-16 14:24:12|
Take a look to the deliverables list in detail: detailed list of transMed deliverables.
|year||authors and title||journal||last update|
Erico Himawan, Per EkstrÃ¶m, Matej Buzgo, Pieter Gaillard, Einar StefÃ¡nsson, Valeria Marigo, Thorsteinn Loftsson, FranÃ§ois Paquet-Durand
Drug delivery to retinal photoreceptors
published pages: 1637-1643, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.03.004
|Drug Discovery Today 24/8||2020-02-04|
Arianna Tolone, Soumaya Belhadj, Andreas Rentsch, Frank Schwede, FranÃ§ois Paquet-Durand
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
published pages: 453, ISSN: 2073-4425, DOI: 10.3390/genes10060453
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSMED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRANSMED" are provided by the European Opendata Portal: CORDIS opendata.